目的：探讨康柏西普眼用注射液(Conbercept ophthalmic injection，COI)玻璃体内注射联合激光治疗对糖尿病性黄斑水肿(diabetic macular edema，DME)患者的有效性及安全性。

方法：纳入2016-08/2018-06我院眼科收治的DME患者，依据患者施行激光治疗是否联合COI分为观察组(激光治疗联合COI)55例55眼和对照组(仅激光治疗)50例50眼，对比两组患者术后1mo的BCVA(LogMAR)、黄斑中心凹视网膜厚度(CMT)、眼压水平及视野、30°视野平均光阈值敏感度、视野平均缺损值水平变化。

结果：两组患者治疗前一般资料比较无差异(P>0.05)，两组患者BCVA(0.63±0.13 vs 0.76±0.19； t=4.123，P<0.001)、CMT(305.89±58.76 vs 340.26±60.41μm； t=2.954，P=0.004)比较有差异，而两组患者眼压对比(12.11±1.82 vs 12.24±1.59mmHg； t=0.389，P=0.700)无差异； 观察组患者术后1mo视野灰度值、视野平均缺损值显著低于对照组(P<0.001)； 观察组患者术后1mo 30°视野平均光阈值敏感度显著高于对照组(P<0.001)。

结论：玻璃体内注射康柏西普眼用注射液联合激光治疗糖尿病性黄斑水肿患者有效且安全。

METHODS: In the DME patients admitted to our hospital in August 2016 to June 2018, according to whether the patients were treated with photocoagulation treatment or not, the patients was divided into observation group(photocoagulation treatment combined with COI)in 55 cases of 55 eyes and control group(photocoagulation treatment without COI)in 50 cases, 50 eyes. The clinical outcomes of the two groups after surgery included the best corrected visual acuity(BCVA), foveal retinal thickness(CMT), intraocular pressure and visual field, 30° visual field average light threshold sensitivity, and visual field mean defect value.

RESULTS: There was no significant difference in the general data between the two groups(P>0.05). There were statistically significant differences on BCVA(0.63±0.13 vs 0.76±0.19; t=4.123, P<0.001), CMT(305.89±58.76 vs 340.26±60.41μm; t=2.954, P=0.004)between observation group and control group, but there was no significant difference between the two groups in the intraocular pressure(12.11±1.82 vs 12.24±1.59mmHg; t=0.389, P=0.700). The value of visual field and the mean visual field defect of the observation group were significantly lower than those of the control group at 1mo after operation(P<0.001). The average light threshold sensitivity of the observation group was significantly higher at 30° 1mo after operation than that of the control group, the difference was statistically significant(P<0.001).

CONCLUSION: Conbercept ophthalmic injection combined with photocoagulation can improve the efficacy and safety of the treatment for diabetic macular edema in diabetic macular edema patients.